This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Antidepressant Treatment and Global Tests of Coagulation and Fibrinolysis

Florian Lederbogen, Bettina Weber, Michael Colla, Isabella Heuser, Michael Deuschle, and Carl-Erik Dempfle

Published: February 2, 2001

Article Abstract

Letter to the Editor

Sir: Although rare, an increased tendency for bleeding has been associated with various antidepressants, causing justifiable concern. Knowledge about the mechanisms underlying this phenomenon is scarce. The phenomenon is believed to represent interactions of drugs with other drugs or with the serotonergic system of platelets. Furthermore, there is some evidence that depressive disorders by themselves may affect hemostatic function. To further our understanding of the clotting cascade during antidepressant treatment, we analyzed global tests of coagulation and fibrinolysis before and after treatment with either amitriptyline, a tricyclic compound, or paroxetine, which is characterized predominantly by its mode of action, namely selective serotonin reuptake inhibition.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...